16848-19-4

Upstream product

• 13964-23-3 3-azido-3-deoxy-1,2:5,6-di-(O-isopropylidene)-α-D-glucofuranose 
• 16667-96-2 1,2,5,6-di-O-isopropylidene-α-D-glucofuranose-3-O-(S-methylxanthate) 
• 27581-57-3 3-azido-3-deoxy-1,2:5,6-di-O-isopropylidene-α-D-glucofuranose 
• 2280-44-6 D-Glucose 
• 141903-85-7 3β-<((trifluoromethyl)phenylmethyl)imino>-3-deoxy-1,2:5,6-di-O-isopropylidene-D-glucofuranose 
• 4572-32-1 3-O-p-bromobenzenesulfonate of 1,2:5,6-di-O-isopropylidene-α-D-allofuranose 
• 82893-04-7 C₃₀H₃₄O₆P⁽¹⁺⁾*N₃^(1-) 
• 68922-46-3 (1,2;5,6-Di-O-isopropyliden-α-D-glucofuranos-3-yloxy)phosphonium-iodid 
• 6027-62-9 3-deoxy-3-iodo-1,2:5,6-di-O-isopropylidene-α-D-allofuranose 
• 380911-39-7 1,2:5,6-di-O-isopropylidene-3-triflyl-α-D-glucofuranose 
• 3253-75-6 1,2:5,6-di-O-isopropylidene-3-O-tosyl-α-D-glucofuranoside 
• 141903-84-6 3-((4-methoxyphenyl)telluro)-3-deoxy-1,2:5,6-di-O-isopropylidene-D-glucofuranose 
• 582-52-5 1,2:5,6-di-O-isopropylidene-α-D-glucofuranose 
• 3253-75-6 1,2,5,6-di-O-isopropylidene-3-O-(p-toluenesulfonyl)-α-D-allofuranose 

Downstream Products

• 25791-21-3 3-benzyloxycarbonylamino-3-deoxy-1,2:5,6-di-O-isopropylidene-α-D-allo-1,4-furanose 
• 951775-31-8 1,2;5,6-di-O-isopropylidene-3-deoxy-3-{[(2-trifluoromethylphenyl)-methyl]carbonyl}-amino-α-D-allofuranoside 
• 180404-53-9 3-deoxy-1,2:5,6-di-O-isopropylidene-3-(3-phenylthioureido)-α-D-glucofuranose 
• 7508-81-8 [(3aR,5S,6S,6aR)-5-((R)-2,2-Dimethyl-[1,3]dioxolan-4-yl)-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-6-yl]-carbamic acid benzyl ester 
• 846549-48-2 N-[(3aR,5S,6S,6aR)-5-((R)-2,2-Dimethyl-[1,3]dioxolan-4-yl)-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-6-yl]-4-methyl-benzenesulfonamide 
• 869064-91-5 3,5,6-trideoxy-3-(2-bromobenzylmethoxycarbonylamino)-1,2-O-isopropylidene-α-D-xylo-hexenofuranoside 
• 869064-92-6 3,5,6-trideoxy-3-(2-bromo-5-methoxybenzylmethoxycarbonylamino)-1,2-O-isopropylidene-α-D-xylo-hexenofuranoside 
• 869064-88-0 3-deoxy-3-(2-bromobenzylmethoxycarbonylamino)-1,2:5,6-di-O-isopropylidene-α-D-glucofuranoside 
• 869064-86-8 3,5,6-trideoxy-3-(2-bromobenzyl-para-toluenesulfonylamino)-1,2-O-isopropylidene-α-D-xylo-hexenofuranoside 
• 869064-87-9 3,5,6-trideoxy-3-(2-bromo-5-methoxybenzyl-para-toluenesulfonylamino)-1,2-O-isopropylidene-α-D-xylo-hexenofuranoside 
• 869064-84-6 3-deoxy-3-(2-bromobenzyl-para-toluenesulfonylamino)-1,2:5,6-di-O-isopropylidene-α-D-glucofuranoside 
• 869064-85-7 3-deoxy-3-(2-bromo-5-methoxybenzyl-para-toluenesulfonylamino)-1,2:5,6-di-O-isopropylidene-α-D-glucofuranoside 
• 200344-23-6 N-Allyl-N-((3aR,5S,6S,6aR)-5-formyl-2,2-dimethyl-tetrahydro-furo[2,3-d][1,3]dioxol-6-yl)-4-methyl-benzenesulfonamide 
• 200344-27-0 (5aS,6R,7R,8aR)-1-benzyl-5-p-toluenesulphonyl-1,3,3a,5a,6,7,8a,8b-octahydro-6,7-isopropylidenedioxy-4H-furo[2',3':5,6]pyrido[4,3-c]isoxazole 

Relevant academic research and scientific papers

NEW SYNTHETIC "TRICKS". (Et3NH)(Sn(SPh)3) AND Bu2SnH2, TWO USEFUL REAGENTS FOR THE REDUCTION OF AZIDES TO AMINES

Treatment of Sn(SPh)2 with PhSH and Et3N affords a tin(II) complex, soluble in organic solvents, wich is the best reducing agent for azides reported so far.Bu2SnH2, although not so reactive, also shows several advantages with regard to the standard reducing agents for azides, such as its solubility in most solvents or its scarce reactivity with water.

Gabriel-Cromwell aziridination of amino sugars; chiral ferrocenoyl-aziridinyl sugar synthesis and their biological evaluation

N-sugar substituted chiral aziridines were synthesized via Gabriel-Cromwell reaction. Novel pure diastereomers of aziridine derivatives (4 diastereomers) were readily obtained in high yields and their structures were confirmed by means of 1H NM

Synthesis and biological evaluation of novel urea, thiourea and squaramide diastereomers possessing sugar backbone

A series of novel chiral 14 urea, thiourea and squaramide stereoisomers possessing carbohydrate backbones as well as amide functional groups was synthesized and characterized by their, 1H NMR, 13C NMR, FT-IR, HRMS, optical rotation, and melting points. Their antiproliferative activities were investigated against HeLa and PC3 cell lines. The compounds 9, 11 and 12 showed better activities at 25 μM against PC3 cell line with respect to the standard 5-fluorouracil (5-FU). Especially, the compounds 9 and 11 showed higher activities than the standard 5-FU even at low concentration (5 μM) against HeLa cell line. IC50 results also confirm these activities. The compounds 9, 10 and 11 have the IC50 values of 1.10 μM, 1.51 μM and 1.02 μM, respectively while 5-FU has 2.51 μM. Moreover, their cytotoxicity tests have proven that their viabilities were in between 50% and 100%.

A method for preparing N-alkylated kanosamines from diacetone D-glucose

The aminoglycoside (AG) antibiotics have seen a resurgence in their clinical use given the increase in multi drug resistant bacterial infections. Campaigns to generate novel analogs show promise that structural modification can lead to compounds with improved pharmacological properties. The results described herein include a new method to synthesize mono-, di-, and mixed N-alkylated kanosamine sugars and their elaboration into novel glycosides that inhibit bacterial protein synthesis in vitro.

2,2′-Bipyridine-3,3′-dicarboxylic carbohydrate esters and amides. Synthesis and preliminary evaluation as ligands in Cu(II)-catalysed enantioselective electrophilic fluorination

A series of 10 new carbohydrate-substituted bipyridines were prepared from 2,2′-bipyridine-3,3′-dicarboxylic acid, itself easily available from ortho-phenanthroline. As a preliminary exploration of their use as chiral ligands, Cu(II)-catalysed asymmetric electrophilic fluorination of model β-ketoesters using these simple and easily accessible chiral bipyridines was studied. Only modest enantioselectivity was observed in this reaction, although the ee was in a similar range as those provided by known and more elaborate ligands.

Monosaccharide Derivatives as Anti-Inflammatory and/or Anti-Cancer Agents

The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases su

Synthesis and antibacterial activity of aminodeoxyglucose derivatives against Listeria innocua and Salmonella typhimurium

In this study aminodeoxyglucose derivatives were synthesized and evaluated for their antibacterial activity against two food bacteria, Listeria innocua and Salmonella typhimurium. 6-Amino-6-deoxy-α-Dmethylglucopyranose (GSA-6), 3-amino-3-deoxy-D-glucopyranoside (GSA-3), and β-D-glucopyranosylamine (GSA-1) were synthesized and concurrently tested with commercially available D-glucosamine (GSA-2) for antibacterial activity. Results obtained from this study showed a pronounced antagonist effect due to the position of amino groups of aminoglucose derivatives on the antibacterial activity. GSA-3 was the most active compound. At a concentration of 2 × 10 -4 mol mL -1, it delayed the growth of both bacteria with percentages of inhibition of 29 and 15% for L. innocua and S. typhimurium, respectively. At the same concentration the percentages of inhibition for other aminodeoxyglucoses varied between 5 and 18% and between 2 and 11% for L. innocua and S. typhimurium, respectively. All compounds were characterized by FTIR, 1H NMR, and 13C NMR spectroscopy.

MONOSACCHARIDE DERIVATIVES

The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases su

MONOSACCHARIDE DERIVATIVES AS ANTI-INFLAMMATORY AND/OR ANTI-CANCER AGENTS

The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases su

MONOSACCHARIDE DERIVATIVES AS ANTI-INFLAMMATORY AND/OR ANTI-CANCER AGENTS

The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disorder herein can be useful for inhibition and prevention of inflammation and associated pathologies including inflammatory and autoimmune diseases su